PropThink’s Lead Stories in Biotech
Long Ideas - On Friday, PropThink launched its database of Special Protocol Assessments, or SPAs. These trials are, in essence, a FDA-blessed measure to mitigate clinical efficacy risk … Continue Reading
Read NowLong Ideas
No Major Earnings Surprises, but InterMune is Cash-Rich and An Interesting Trade
Long Ideas - A month after raking in more than $225M through a combination of debt and equity sales, InterMune’s (ITMN) 2012 financial results released Thursday contain little … Continue Reading
Read NowDon’t Tune Out; Pharmacyclics’ Move Higher Isn’t Over Yet
Long Ideas - Just over a week has passed since our last report on Pharmacyclics (PCYC), in which we argued that the stock has solid upside potential based … Continue Reading
Read NowQuestcor: Firing on All Cylinders, Earnings Next Tuesday, Shorts Covering
Long Ideas - Shares of Questcor Pharmaceuticals (QCOR) have started to rise to more realistic valuations in the new year (as PropThink expected), breaking $31 dollars on Tuesday … Continue Reading
Read NowFDA Changes Stance, Favors NDA Resubmission for CHTP’s Northera
Long Ideas - Shares of Chelsea Therapeutics (CHTP) opened sharply higher on news Wednesday that FDA has provided the company with a new pathway for approval of Northera. … Continue Reading
Read NowAs We Expected, Chiesi Moves to Acquire Cornerstone Therapeutics
Long Ideas - To those following the story (and PropThink’s coverage), it should come as little surprise that Cornerstone Therapeutics’ (CRTX) majority shareholder Chiesi Farmaceutici SpA is making … Continue Reading
Read NowOpportunity Knocks: Trading Raptor Pharma’s Recent Fall-Off
Long Ideas - Short interest in Raptor Pharmaceuticals (RPTP) increased by 6% over the last two months, in tandem with the stock’s rise to $6.28, which has since … Continue Reading
Read Now